| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| ln Vivo |
Oral administration of siberianone B, millelin, siberian sugar A5, siberian sugar A6, ginsenoside A, ginsenoside Re, and ginsenoside Rb1 demonstrated the effectiveness of siberianone B in both normal and AD rats after the new powder was opened. Rats' pharmacokinetic characteristics did not differ significantly [1].
|
|---|---|
| Animal Protocol |
- Induction of Alzheimer's disease (AD) model in rats: Male Sprague-Dawley rats (280±20 g) were randomly divided into normal and AD model groups. AD was induced by intraperitoneal injection of D-galactose (50 mg/kg/day) for six weeks, combined with bilateral hippocampal injection of amyloid β-peptide fragment 25-35 (Aβ25-35, 4 μg in 4 μL per side) at the end of the fourth week. Normal rats received equivalent volumes of saline. Two weeks after the hippocampal injection, Morris water maze testing and histopathological examination confirmed successful AD modeling. [1]
- Pharmacokinetic study: Rats were fasted overnight with free access to water before oral administration of KXS decoction at a dose of 10 g crude drug per kg body weight. Blood samples were collected from the suborbital vein into heparinized tubes at pre-dose and at 0.083, 0.17, 0.33, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 h post-administration. Plasma was separated by centrifugation at 5000 rpm for 10 min and stored at -80°C until analysis. The plasma concentrations of sibiricaxanthone B were determined by a validated UFLC-MS/MS method. [1] |
| ADME/Pharmacokinetics |
After oral administration of Kai-Xin-San (10 g/kg) to normal rats, the pharmacokinetic parameters of sibiricaxanthone B were: AUC0-t = 146.5 ± 17.9 ng·h/mL, AUC0-∞ = 158.1 ± 22.9 ng·h/mL, Cmax = 75.30 ± 9.10 ng/mL, Tmax = 0.28 ± 0.17 h, T1/2 = 4.62 ± 2.82 h. [1]
In Alzheimer's disease rats, the parameters were: AUC0-t = 134.1 ± 44.2 ng·h/mL, AUC0-∞ = 159.2 ± 58.1 ng·h/mL, Cmax = 58.64 ± 36.60 ng/mL, Tmax = 0.15 ± 0.10 h, T1/2 = 6.52 ± 7.61 h. No statistically significant differences were observed between normal and AD rats for sibiricaxanthone B. [1] |
| References | |
| Additional Infomation |
Siberian flavonoid B is a type of flavonoid compound. It has been reported that Siberian flavonoid B exists in Polygala tenuifolia and Polygala siberiana, and relevant data are available for reference.
sibiricaxanthone B is one of the eight bioactive components quantified in rat plasma after oral administration of Kai-Xin-San using the developed UFLC-MS/MS method. It was found to possess good absorption in vivo according to previous research (not detailed in this paper). In the comparative pharmacokinetic study, no significant differences in the pharmacokinetic parameters of sibiricaxanthone B were observed between normal and Alzheimer's disease rats, unlike some other components such as polygalaxanthone III, tenuifolin, sibiricose A6, ginsenoside Re, and ginsenoside Rb1 which showed better absorption in the AD group. [1] |
| Molecular Formula |
C24H26O14
|
|---|---|
| Molecular Weight |
538.4548
|
| Exact Mass |
538.132
|
| CAS # |
241125-81-5
|
| PubChem CID |
21581293
|
| Appearance |
Light yellow to green yellow solid
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
964.4±65.0 °C at 760 mmHg
|
| Flash Point |
328.7±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.787
|
| LogP |
0.14
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
38
|
| Complexity |
860
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O([C@@]1([H])[C@@]([H])([C@@](C([H])([H])O[H])(C([H])([H])O1)O[H])O[H])[C@@]1([H])[C@]([H])(C2C(=C([H])C3=C(C(C4C([H])=C(C([H])=C([H])C=4O3)O[H])=O)C=2O[H])O[H])O[C@]([H])(C([H])([H])O[H])[C@]([H])([C@]1([H])O[H])O[H]
|
| InChi Key |
LLMCZIBSELEBMK-UKHOTDCGSA-N
|
| InChi Code |
InChI=1S/C24H26O14/c25-5-13-17(30)19(32)21(38-23-22(33)24(34,6-26)7-35-23)20(37-13)14-10(28)4-12-15(18(14)31)16(29)9-3-8(27)1-2-11(9)36-12/h1-4,13,17,19-23,25-28,30-34H,5-7H2/t13-,17-,19+,20+,21-,22+,23+,24-/m1/s1
|
| Chemical Name |
2-[(2S,3R,4S,5S,6R)-3-[(2S,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-1,3,7-trihydroxyxanthen-9-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~185.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8572 mL | 9.2859 mL | 18.5718 mL | |
| 5 mM | 0.3714 mL | 1.8572 mL | 3.7144 mL | |
| 10 mM | 0.1857 mL | 0.9286 mL | 1.8572 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
